Hopkins Med News Update

NEWS STORIES IN THIS ISSUE:

-Study: Race and Ethnicity May Impact Prevalence and Treatment of Heart Valve Dysfunction
-Johns Hopkins Medicine Suggests Eliminating Nerve Cell Protein May Stop ALS, Dementia
-Researchers Tell Doctors to Avoid Routine Urinary Tests for Older Patients with Delirium
-Johns Hopkins Medicine Researchers Show How Air Pollution May Cause Chronic Sinusitis
-Researchers ID Location on Brain Protein Linked to Parkinson’s Disease Development
-COVID-19 News: The Return of Onsite Schooling — and How to Keep Your Kids Safe from COVID

CRF Will Hold Free Online Seminar on Heart Disease Warning Signs

The Cardiovascular Research Foundation (CRF) will hold a free online seminar, “Get Heart Smart,” on August 24 hosted by Drs. Nisha Jhalani and Ajay Kirtane, renowned academic cardiologists from NewYork-Presbyterian/Columbia University Irving Medical Center. The seminar, part of a series of “Mini Med Schools” conducted by the CRF Women’s Heart Health Initiative, will focus on common heart disease symptoms, when to talk to your doctor, and when to seek emergency care.

NEJM: Transcatheter Aortic Valve Replacement Shows Similar Safety Outcomes as Open-Heart Surgery

A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.

PCR and TCT Announce the Creation of a New Educational Program: Partners in Learning

PCR and TCT are proud to announce the creation of a new educational program: “Partners in Learning.” The first of its kind will focus on TAVI practitioners, taking place on 21-22 March 2020 in Sao Paulo, Brazil. It is the first ever stand-alone collaboration between TCT, PCR, and a regional core team of leading practitioners.

New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis

The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.

New Five-Year Data Shows Similar Outcomes for TAVR and SAVR in Patients with Severe Aortic Stenosis and Intermediate Surgical Risk

Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.